India has cleared a major milestone in neurological healthcare by approving Eli Lilly’s novel Alzheimer’s medication, marking a pivotal step in expanding access to advanced cognitive-decline therapies. The approval introduces a treatment option designed to slow the progression of early-stage Alzheimer’s disease, offering renewed hope to patients, families, and healthcare providers contending with one of the world’s most challenging neurodegenerative conditions.
